Hypersensitivity News and Research

RSS

Hypersensitivity is an exaggerated response by the immune system to a drug or other substance.

Cleaning product-related asthma goes beyond irritation

Research from Belgium indicates that a substantial proportion of those who have occupational asthma related to cleaning agents have specific airway sensitivity to the components of detergents.

27 Sep 2013

Japanese MHLW approves Hizentra for treatment of primary and secondary immunodeficiencies

CSL Behring announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Hizentra (Immune Globulin Subcutaneous [Human]) for the treatment of primary immunodeficiency (PID) and for the treatment of secondary immunodeficiency (SID). Hizentra is now the first and only 20 percent subcutaneous immunoglobulin (SCIg) therapy in the world for the treatment of these conditions, both of which belong to group of rare and serious diseases of the immune system.

27 Sep 2013

Electroacupuncture treatment improves visceral hypersensitivity in irritable bowel syndrome

Irritable bowel syndrome patients extensively suffer from chronic visceral hypersensitivity, with involvement of all levels of the brain-gut axis, as well as various neurotransmitters.

12 Sep 2013

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

10 Sep 2013

"Millions Suffer, Few Understand" encourages patients to talk openly about IC/BPS

This September, patients around the world will unite to share their personal stories and struggles with interstitial cystitis / bladder pain syndrome (IC/BPS). The 2013 theme, "Millions Suffer, Few Understand" encourages patients and providers to talk openly about this common yet often misunderstood pelvic pain condition.

5 Sep 2013

Scientists provide insights into compound that may prevent noise-related damage

Your mother was right when she warned you that loud music could damage your hearing, but now scientists have discovered exactly what gets damaged and how. In a research report published in the September 2013 issue of The FASEB Journal, scientists describe exactly what type of damage noise does to the inner ear, and provide insights into a compound that may prevent noise-related damage.

30 Aug 2013

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO).

29 Aug 2013

FDA approves Galderma's Mirvaso topical gel for facial erythema of rosacea

Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013.

27 Aug 2013

FDA grants marketing approval for VALCHLOR gel for treatment of early stage CTCL

Ceptaris Therapeutics, Inc., a privately held, specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for the orphan drug VALCHLOR (mechlorethamine) gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.

26 Aug 2013

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital, an internationally recognized teaching affiliate of Harvard Medical School known for its excellence in patient care, medical research and training of outstanding young health professionals.

17 Aug 2013

Neurologists appear unaware of serious safety risks associated with anti-epilepsy drugs

A study by Johns Hopkins researchers shows that a fifth of U.S. neurologists appear unaware of serious drug safety risks associated with various anti-epilepsy drugs, potentially jeopardizing the health of patients who could be just as effectively treated with safer alternative medications.

16 Aug 2013

FDA: New drug Tivicay approved to treat HIV-1 infection

The U.S. Food and Drug Administration today approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection. Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply.

13 Aug 2013

Cancer-linked mitosis: an interview with Professor Scott Kern, Johns Hopkins University School of Medicine

Mitosis is the process by which a cell gives rise to two daughter cells. It’s the basis behind the growth of the human body, the renewal of the human body as it ages, and unfortunately, the growth of cancers.

7 Aug 2013

Lupin acquires exclusive license to promote, distribute Romark's Alinia for Oral Suspension in US

Romark Laboratories announced that it has entered into a strategic agreement with Lupin Limited and its subsidiaries (collectively Lupin) designed to expand promotion and distribution efforts related to its Alinia (nitazoxanide) for Oral Suspension, 100 mg/5 mL. Under the agreement, Lupin acquired an exclusive license to promote and distribute Alinia for Oral Suspension in the United States.

7 Aug 2013

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema, EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two months (after 5 initial monthly injections) achieved the primary endpoint of a significantly greater improvement in best-corrected visual acuity from baseline compared to laser photocoagulation at 52 weeks.

6 Aug 2013

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Forest Laboratories, Inc. and Pierre Fabre Laboratories announced today that FETZIMA (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor, discovered by Pierre Fabre Laboratories and co-developed by Forest Laboratories, Inc. was approved by the U.S. Food and Drug Administration for the treatment of Major Depressive Disorder in adults.

26 Jul 2013

Study finds that higher-frequency electric current stimulation of the spinal cord reduces pain faster

An animal study in the August issue of Anesthesiology suggests that higher-frequency electric current stimulation of the spinal cord reduced pain quicker and better reached nerves not affected by traditionally used frequencies. A higher frequency and intensity controlled pain faster and more effectively, the study found.

25 Jul 2013

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for fenofibric acid EQ 45 mg and EQ 135 mg delayed-release capsules.

19 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.

17 Jul 2013